Abacavir sulfate lamivudine has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Abacavir sulfate lamivudine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
EPV40001 IV Open-Label, Pilot Study To Explore The Early Antiviral Activity And Tolerability Of Abacavir And Epivir When Each Is Administered Once-Daily Within A Triple Combination Regimen Including Abacavir, Epivir And Retrovir Compared to The Triple Combination Regimen Administered Twice-Daily In Antiretroviral Naïve, HIV-1 Infected Subjects (48 Week Report).
EPZ104057 IV A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Combination with Kaletra in Antiretroviral-Naïve HIV-1 Infected Subjects
WE066, EPI40007 IV The Antiretroviral Pregnancy Registry (APR, Registry)
CAL30001 III A Phase III, Randomized, Open-Label, Parallel, Multi-center Study to Evaluate Treatment with Fixed-Dose Combination of Abacavir/Lamivudine (600mg/300mg) Once-Daily versus Abacavir (300mg) Twice-Daily and Lamivudine (300mg) Once-Daily in Combination with Tenofovir Once-Daily and a New PI or NNRTI for 48 Weeks in ART-Experienced HIV-1 Infected Patients
ESS101822 III A Phase IIIB, Randomized, Open-Label, Multicenter, Parallel-Arm Study to Evaluate the Short-Term Safety and Tolerability of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered Once-Daily or the Separate Abacavir and Lamivudine Tablets Administered Twice-Daily, as Part of a Three or Four Drug Regimen, in Antiretroviral-Naïve HIV-1 Infected Subjects.
ESS30008 III A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretroviral Experienced Patients
ESS30009 III A Phase III, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-Dose Combination Tablet as a Once-Daily Regimen in Antiretroviral-Naïve HIV-1 Infected Subjects